Maynard Um
-
-
-
-
-
-
-
Jones Trading Reiterates Buy Rating on Capricor Therapeutics (CAPR) as FDA review resumed
-
-
-
-
-
-
-
Capricor Therapeutics (CAPR) Reiterated at Overweight by Cantor Fitzgerald
-
-
-
-
-
-
-
Capricor Therapeutics (CAPR) PT Raised to $51 at Jones Trading
-
-
-
-
-
-
-
Capricor Therapeutics (CAPR) Mentioned as Short by Shkreli
-
-
-
-
-
-
-
Jones Trading Reiterates Buy Rating on Capricor Therapeutics (CAPR)
-
-
-
-
-
-
-
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
-
-
-
-
-
-
Roth/MKM Comments on Capricor Therapeutics (CAPR)
-
396,422 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

